Moreover, our observation of decreased Taxol sensitivity in BUB1B-edited cells is in line with the finetuned balance between CIN levels and cell fate, where high CIN levels compromise response to Taxol-based therapies [45, 46], potentially highlighting the ineffectiveness of Taxol-based therapies for the treatment of carcinomas arising in carriers of “deleterious” BUB1B variants. This evidence concerns the gene BUB1B and carcinoma.